Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and 10-Day Decitabine in AML, MDS, CMML, and BPDCN
NCT03404193Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2018
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML), mixed phenotype acute leukemia (MPAL), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2018; status: terminated.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)chronic myelomonocytic leukemia (CMML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT03404193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404193.